Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity.
Epistasis
Genetic risk factors
Late toxicity
Prostate cancer
Radiotherapy
SNPs
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
24
12
2020
revised:
19
02
2021
accepted:
17
03
2021
pubmed:
11
4
2021
medline:
29
6
2021
entrez:
10
4
2021
Statut:
ppublish
Résumé
To identify the effect of single nucleotide polymorphism (SNP) interactions on the risk of toxicity following radiotherapy (RT) for prostate cancer (PCa) and propose a new method for polygenic risk score incorporating SNP-SNP interactions (PRSi). Analysis included the REQUITE PCa cohort that received external beam RT and was followed for 2 years. Late toxicity endpoints were: rectal bleeding, urinary frequency, haematuria, nocturia, decreased urinary stream. Among 43 literature-identified SNPs, the 30% most strongly associated with each toxicity were tested. SNP-SNP combinations (named SNP-allele sets) seen in ≥10% of the cohort were condensed into risk (RS) and protection (PS) scores, respectively indicating increased or decreased toxicity risk. Performance of RS and PS was evaluated by logistic regression. RS and PS were then combined into a single PRSi evaluated by area under the receiver operating characteristic curve (AUC). Among 1,387 analysed patients, toxicity rates were 11.7% (rectal bleeding), 4.0% (urinary frequency), 5.5% (haematuria), 7.8% (nocturia) and 17.1% (decreased urinary stream). RS and PS combined 8 to 15 different SNP-allele sets, depending on the toxicity endpoint. Distributions of PRSi differed significantly in patients with/without toxicity with AUCs ranging from 0.61 to 0.78. PRSi was better than the classical summed PRS, particularly for the urinary frequency, haematuria and decreased urinary stream endpoints. Our method incorporates SNP-SNP interactions when calculating PRS for radiotherapy toxicity. Our approach is better than classical summation in discriminating patients with toxicity and should enable incorporating genetic information to improve normal tissue complication probability models.
Identifiants
pubmed: 33838170
pii: S0167-8140(21)06161-2
doi: 10.1016/j.radonc.2021.03.024
pmc: PMC8754257
mid: NIHMS1767939
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
241-248Subventions
Organisme : NCI NIH HHS
ID : K07 CA187546
Pays : United States
Investigateurs
Yolande Lievens
(Y)
Marc van Eijkeren
(M)
Christel Monten
(C)
Wilfried De Neve
(W)
Stephanie Peeters
(S)
Caroline Weltens
(C)
Gilles Defraene
(G)
Erik van Limberghen
(E)
Erik Briers
(E)
Celine Bourgier
(C)
Roxana Draghici
(R)
Francoise Bons
(F)
Thomas Blaschke
(T)
Christian Weiß
(C)
Irmgard Helmbold
(I)
Christian Weißenberger
(C)
Petra Stegmaier
(P)
Johannes Claßen
(J)
Ulrich Giesche
(U)
Marie-Luise Sautter-Bihl
(ML)
Burkhard Neu
(B)
Thomas Schnabel
(T)
Michael Ehmann
(M)
Benjamin Gauter-Fleckenstein
(B)
Jörg Schäfer
(J)
Tommaso Giandini
(T)
Marzia Franceschini
(M)
Claudia Sangalli
(C)
Sara Morlino
(S)
Laura Lozza
(L)
Maria C De Santis
(MC)
Gabriele Pietro
(G)
Elena Delmastro
(E)
Elisabetta Garibaldi
(E)
Alessandro Cicchetti
(A)
Bibiana Piqué-Leiva
(B)
Meritxel Molla
(M)
Alexandra Giraldo
(A)
Monica Ramos
(M)
Ramon Lobato-Busto
(R)
Laura Torrado Moya
(L)
Isabel Dominguez-Rios
(I)
Irene Fajardo-Paneque
(I)
Patricia Calvo-Crespo
(P)
Ana Carballo
(A)
Paula Peleteiro
(P)
None Olivia-Fuentes-Rios
Antonio Gomez-Caamano
(A)
Victoria Harrop
(V)
Debbie Payne
(D)
Manjusha Keni
(M)
Paul R Symonds
(PR)
Samuel Lavers
(S)
Simon Wright
(S)
Sridhar Thiagarajan
(S)
Luis Aznar-Garcia
(L)
Kiran Kancherla
(K)
Christopher Kent
(C)
Subramaniam Vasanthan
(S)
Donna Appleton
(D)
Monika Kaushik
(M)
Frances Kenny
(F)
Hazem Khout
(H)
Jaroslaw Krupa
(J)
Kelly V Lambert
(KV)
Simon Pilgrim
(S)
Sheila Shokuhi
(S)
Kalliope Valassiadou
(K)
Ion Bioangiu
(I)
Kufre Sampson
(K)
Ahmed Osman
(A)
Corinne Faivre-Finn
(C)
Karen Foweraker
(K)
Abigail Pascoe
(A)
Claire P Esler
(CP)
Tim Ward
(T)
Daniel S Higginson
(DS)
Sheryl Green
(S)
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Acta Oncol. 2018 Nov;57(11):1499-1505
pubmed: 29952681
Clin Oncol (R Coll Radiol). 2014 Dec;26(12):739-42
pubmed: 25267305
G3 (Bethesda). 2016 Jul 07;6(7):2043-50
pubmed: 27185397
Front Oncol. 2020 Oct 15;10:541281
pubmed: 33178576
Front Oncol. 2017 Apr 27;7:83
pubmed: 28497027
Hum Mol Genet. 2019 Nov 21;28(R2):R143-R150
pubmed: 31504522
Brief Funct Genomics. 2015 Mar;14(2):143-55
pubmed: 25241224
J Natl Cancer Inst. 2020 Feb 1;112(2):179-190
pubmed: 31095341
Front Oncol. 2018 Jun 21;8:228
pubmed: 29977864
BMC Cancer. 2006 May 03;6:114
pubmed: 16672066
Bioinformatics. 2015 May 1;31(9):1466-8
pubmed: 25550326
Radiother Oncol. 2019 Sep;138:59-67
pubmed: 31146072
Cardiovasc Drugs Ther. 2021 Jun;35(3):627-635
pubmed: 33156471
Trends Genet. 2013 Dec;29(12):669-76
pubmed: 24161664
PLoS Genet. 2013 Mar;9(3):e1003348
pubmed: 23555274
Circ Cardiovasc Genet. 2010 Oct;3(5):468-74
pubmed: 20729558
Radiother Oncol. 2017 Oct;125(1):107-112
pubmed: 28823404
Hum Mol Genet. 2002 Oct 1;11(20):2463-8
pubmed: 12351582
BMC Med Genet. 2017 Oct 3;18(1):107
pubmed: 28974197
Nat Genet. 2018 Sep;50(9):1219-1224
pubmed: 30104762
Hum Hered. 2003;56(1-3):73-82
pubmed: 14614241
Sci Rep. 2017 Feb 24;7:43381
pubmed: 28233873